Sanjiv Patel, Relay CEO
Relay reaps $400M IPO windfall after drawing the curtain on motion-based drug design pipeline
A red-hot venture market back in 2018 propelled Relay Therapeutics to a whopping $400 million crossover round. And now, the biotech is riding on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
